| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.04 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.04 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.04 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.04 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.12 | 0.04 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.04 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.04 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.04 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | 0.12 | 0.04 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.084 | 0.04 |